The company intends to allocate the net proceeds toward working capital, specifically targeting research, clinical development, and commercialization efforts. A primary objective of this funding is to support the ongoing advancement of bempikibart, an anti-IL-7Rα antibody currently in Phase 2 trials for the treatment of alopecia areata.
Morgan Stanley, Jefferies, and Cantor are serving as joint book-running managers for the transaction. The offering is being conducted under a shelf registration statement declared effective by the SEC on July 13, 2026. Final terms and the completion of the sale remain subject to prevailing market conditions.
Comments (0)
No comments yet. Be the first!